U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C7H5O3.Mg
Molecular Weight 298.5312
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MAGNESIUM SALICYLATE ANHYDROUS

SMILES

c1ccc(c(c1)C(=O)O)O.c1ccc(c(c1)C(=O)[O-])[O-].[Mg+2]

InChI

InChIKey=MQHWFIOJQSCFNM-UHFFFAOYSA-L
InChI=1S/2C7H6O3.Mg/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula Mg
Molecular Weight 24.3051
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H5O3
Molecular Weight 137.1131
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Salicylic acid is obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics. Salicylic acid treats acne by causing skin cells to slough off more readily, preventing pores from clogging up. This effect on skin cells also makes salicylic acid an active ingredient in several shampoos meant to treat dandruff. Use of straight salicylic solution may cause hyperpigmentation on unpretreated skin for those with darker skin types (Fitzpatrick phototypes IV, V, VI), as well as with the lack of use of a broad spectrum sunblock. Subsalicylate in combination with bismuth form the popular stomach relief aid known commonly as Pepto-Bismol. When combined the two key ingredients help control diarrhea, nausea, heartburn, and even gas. It is also very mildly anti-biotic. Salicylic acid directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. It works by causing the cells of the epidermis to slough off more readily, preventing pores from clogging up, and allowing room for new cell growth. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid inhibits the oxidation of uridine-5-diphosphoglucose (UDPG) competitively with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to the phenolic acceptor. The wound-healing retardation action of salicylates is probably due mainly to its inhibitory action on mucopolysaccharide synthesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.48 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
238 min
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SALICYLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Other AEs: Redness, Scales...
Other AEs:
Redness
Scales
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Scales
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
major
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
In vitro release studies of methyl salicylate from the ointment bases and the commercial dermatological products.
1990
[Identification and quantification of exogenous metabolites in biological liquids with new development in NMR spectroscopy in one and two dimensions].
1999
[Salicylism and glaucoma: reciprocal augmentation of the toxicity of acetazolamide and acetylsalicylic acid].
1999 Feb
Effects of salicylates on evoked otoacoustic emissions and remote masking in humans.
1999 May-Jun
Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis.
1999 Sep
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.
2001
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
A novel jasmonic acid-inducible rice myb gene associates with fungal infection and host cell death.
2001 Apr
Abnormal callose response phenotype and hypersusceptibility to Peronospoara parasitica in defence-compromised arabidopsis nim1-1 and salicylate hydroxylase-expressing plants.
2001 Apr
Nucleotide sequence analysis of 5'-flanking region of salicylate hydroxylase gene, and identification and purification of a LysR-type regulator, SalR.
2001 Apr
Nitric oxide: comparative synthesis and signaling in animal and plant cells.
2001 Apr
[Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
2001 Apr 6
Induction of wound response gene expression in tomato leaves by ionophores.
2001 Feb
Isolation and preliminary characterization of the medium-chain fatty acid:CoA ligase responsible for activation of short- and medium-chain fatty acids in colonic mucosa from swine.
2001 Feb
Non-ionic micellar affinity capillary electrophoresis for analysis of interactions between micelles and drugs.
2001 Feb
Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay.
2001 Feb
Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis.
2001 Feb
Increased leukotriene production by food additives in patients with atopic dermatitis and proven food intolerance.
2001 Feb
Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction.
2001 Feb
Ethylene-dependent salicylic acid regulates an expanded cell death response to a plant pathogen.
2001 Feb
Molecular cloning of the nahG gene encoding salicylate hydroxylase from Pseudomonas fluorescens.
2001 Feb 28
Characterization of PBZ1, a probenazole-inducible gene, in suspension-cultured rice cells.
2001 Jan
Non-uniform mapping of stress-induced, motility-related charge movement in the outer hair cell plasma membrane.
2001 Jan
Manipulation of salicylate content in Arabidopsis thaliana by the expression of an engineered bacterial salicylate synthase.
2001 Jan
Guidelines for the management of cutaneous warts.
2001 Jan
A nuclear casein kinase 2 activity is involved in early events of transcriptional activation induced by salicylic acid in tobacco.
2001 Jan
Reversed-phase high-performance liquid chromatography versus spectrophotometric assay for thimerosal in Cuban recombinant hepatitis B vaccine.
2001 Jan 12
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.
2001 Jan 15
Pathogen-induced expression of plant ATP: citrate lyase.
2001 Jan 19
Development of QSARs to investigate the bacterial toxicity and biotransformation potential of aromatic heterocylic compounds.
2001 Mar
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis.
2001 Mar 1
Selective inhibition of interleukin-4 gene expression in human T cells by aspirin.
2001 Mar 15
Determination of salicylate, gentisic acid and salicyluric acid in human urine by capillary electrophoresis with laser-induced fluorescence detection.
2001 Mar 5
Acanthoamoeba attachment to contact lenses.
2001 May
Anti-inflammatory and antipyretic effects of Trigonella foenum-graecum leaves extract in the rat.
2001 May
Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein.
2001 May
In vitro dermal absorption of methyl salicylate, ethyl parathion, and malathion: first responder safety.
2007 Jun
Patents

Sample Use Guides

adults 18 years and older: apply one patch to affected area and leave in place for up to 8-12 hours; if pain lasts lasts after using the first patch, a second patch may be applied for up to another 8 to 12 hours; use only one patch at a time; do not use more than 2 patches per day; do not use for more 3 days in a row
Route of Administration: Topical
In vitro tests with fresh dermatomed (0.3 to 0.4 mm thick) female breast skin and one leg skin specimen were conducted in Bronaugh flow-through Teflon diffusion cells with three chemicals used to simulate chemical warfare agents: 14C-radiolabeled methyl salicylate (MES), ethyl parathion (PT), and malathion (MT), at three dose levels (2, 20, and 200 mM). Tests were conducted at a skin temperature of 29 degrees C using a brief 30-min exposure to the chemical and a 6.5-h receivor collection period. Rapid absorption of all three chemicals was observed, with MES absorbed about 10-fold faster than PT and MT. For MES, PT, and MT, respectively, there was 32%, 7%, and 12% absorption into the receivor solution at the low dose (2 mM), 17%, 2%, and 3% at the medium dose (20 mM), and 11%, 1%, and 1% at the high dose (200 mM) levels. Including the skin depot for MES, PT, and MT, respectively, there was 40%, 41%, and 21% (low dose), 26%, 16%, and 8% (medium dose), and 13%, 19%, and 10% (high does) absorption.
Substance Class Chemical
Created
by admin
on Sat Jun 26 07:57:19 UTC 2021
Edited
by admin
on Sat Jun 26 07:57:19 UTC 2021
Record UNII
JQ69D454N1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MAGNESIUM SALICYLATE ANHYDROUS
Common Name English
MAGNESIUM, BIS(2-(HYDROXY-.KAPPA.O)BENZOATO-.KAPPA.O)-, (T-4)-
Systematic Name English
MAGAN
Common Name English
MAGNESIUM, BIS(2-HYDROXYBENZOATO-O1,O2)-
Common Name English
LORISAL
Common Name English
ANALATE
Common Name English
MOBIDIN
Common Name English
TRIACT
Common Name English
MAGNESIUM SALICYLATE (1:2)
Systematic Name English
MAGNESIUM SALICYLATE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C257
Created by admin on Sat Jun 26 07:57:19 UTC 2021 , Edited by admin on Sat Jun 26 07:57:19 UTC 2021
Code System Code Type Description
FDA UNII
JQ69D454N1
Created by admin on Sat Jun 26 07:57:19 UTC 2021 , Edited by admin on Sat Jun 26 07:57:19 UTC 2021
PRIMARY
CAS
18917-89-0
Created by admin on Sat Jun 26 07:57:19 UTC 2021 , Edited by admin on Sat Jun 26 07:57:19 UTC 2021
PRIMARY
NCI_THESAURUS
C77361
Created by admin on Sat Jun 26 07:57:19 UTC 2021 , Edited by admin on Sat Jun 26 07:57:19 UTC 2021
PRIMARY
PUBCHEM
64738
Created by admin on Sat Jun 26 07:57:19 UTC 2021 , Edited by admin on Sat Jun 26 07:57:19 UTC 2021
PRIMARY
ECHA (EC/EINECS)
242-669-3
Created by admin on Sat Jun 26 07:57:19 UTC 2021 , Edited by admin on Sat Jun 26 07:57:19 UTC 2021
PRIMARY
MERCK INDEX
M7019
Created by admin on Sat Jun 26 07:57:19 UTC 2021 , Edited by admin on Sat Jun 26 07:57:19 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY